Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403188 · ClinicalTrials.gov registry record
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
A clinical trial of Multiple Sclerosis and Dermatomyositis, sponsored by Kyverna Therapeutics.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT07403188: Recruiting study of Multiple Sclerosis and Dermatomyositis, sponsored by Kyverna Therapeutics.
NCT07403188 is a study of Multiple Sclerosis and Dermatomyositis that is actively recruiting participants, run by Kyverna Therapeutics. The registered enrollment target is 70 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07403188, a study of Multiple Sclerosis and Dermatomyositis, is actively recruiting participants, sponsored by Kyverna Therapeutics.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Conditions Studied
Interventions
- DRUG KYV-101
Study Locations (1)
Colorado
- University of Colorado, Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2041-01 |
What NCT07403188 shows while recruiting
NCT07403188 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower).
The record links to 7 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which KYV-101 is the first listed.
NCT07403188 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT07403188 about?
NCT07403188 is a clinical study titled "A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101". The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product)....
What is the current status of trial NCT07403188?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2025-11-24. Estimated completion is 2041-01.
What conditions does trial NCT07403188 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Dermatomyositis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Myasthaenia Gravis.
What interventions are being tested in trial NCT07403188?
The interventions under investigation include: KYV-101 (DRUG).
Who is sponsoring clinical trial NCT07403188?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07403188 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07403188's enrollment target sits among peer trials
70 154th of 315 higher than 160 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI